Hims & Hers shares rise as company adds new weight-loss medications to platform
Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which have exploded in popularity in recent years. Hims & Hers launched a weight loss program in late 2023, but its GLP-1 offerings have evolved as the company has contended with a volatile supply and regulatory environment.
Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...
Eli Lilly is escalating its legal push to protect the exclusivity of its high-profile weight-loss and diabetes drugs, ...
19hon MSN
Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...
Eli Lilly on Thursday launched in India its diabetes and weight-loss drug, Mounjaro, which has already clocked in over $20 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback